Quantitative risk-benefit analysis of a calcium channel antagonist during regulatory review.

被引：0

|

作者：

Nguyen, B ^{[1
]}

Marroum, PJ ^{[1
]}

Gobburu, JV ^{[1
]}

机构：

[1] US FDA, Rockville, MD 20857 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期

关键词：

D O I：

10.1016/S0009-9236(03)90476-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：P33 / P33

页数：1

相关论文

共 50 条

[21] BIAS IN RISK-BENEFIT ANALYSIS
MAZUR, A
TECHNOLOGY IN SOCIETY, 1985, 7 (01) : 25 - 30
[22] A risk-benefit analysis of vaccination
Heininger, Ulrich
VACCINE, 2009, 27 : G9 - G12
[23] Symmetrical analysis of risk-benefit
Warren, John B.
Day, Simon
Feldschreiber, Peter
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 757 - 761
[24] A risk-benefit analysis of pioglitazone
Reactions Weekly, 2014, 1483 (1) : 2 - 2
[25] EXAMPLES IN RISK-BENEFIT ANALYSIS
WILSON, R
CHEMTECH, 1975, 5 (10) : 604 - 607
[26] Quantitative Risk-Benefit Analysis of Oral Anticoagulants in Patients with Atrial Fibrillation
Hsu, Jason C.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 387 - 387
[27] RISK-BENEFIT ANALYSIS OF MALNUTRITION AND PERIOPERATIVE NUTRITIONAL SUPPORT - A REVIEW
MEGUID, MM
MUGHAL, MM
MEGUID, V
NUTRITION INTERNATIONAL, 1987, 3 (01): : 25 - 34
[28] REGULATORY ASPECTS OF FOOD ADDITIVE RISK-BENEFIT PROBLEM
ROBERTS, HR
FOOD TECHNOLOGY, 1978, 32 (08) : 59 - 61
[29] RISK-BENEFIT ANALYSIS AND THE DETERMINATION OF ACCEPTABLE RISK
DARDIS, R
DAVENPORT, G
KURIN, J
MARR, J
JOURNAL OF CONSUMER AFFAIRS, 1983, 17 (01) : 38 - 56
[30] Prostate Biopsy: A Risk-Benefit Analysis
Loeb, Stacy
JOURNAL OF UROLOGY, 2010, 183 (03): : 852 - 853

← 1 2 3 4 5 →